Illumina Launches Protein Prep for Large-Scale Proteomic Analysis
Illumina, a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function, has introduced Protein Prep. This assay measures up to 9,500 unique human protein targets using next-generation sequencing (NGS). The platform supports biomarker discovery and therapeutic development across cancer, cardiometabolic, and immunologic diseases.
Protein Prep, originally developed and marketed by Bio-Techne, is now integrated into Illumina's sequencing platforms and software tools. This integration streamlines workflows from sample to analysis, making it a powerful tool for large-scale genomics studies. The assay is designed to incorporate proteomic data into these studies, providing a more comprehensive understanding of biological systems.
Protein Prep's ability to measure a vast number of protein targets makes it a valuable tool for researchers. It can help identify biomarkers for early disease detection, monitor disease progression, and predict treatment response. This, in turn, can accelerate therapeutic development and improve patient outcomes.
Illumina's launch of Protein Prep expands the company's portfolio of tools for large-scale analysis. By integrating proteomic data into genomics studies, Protein Prep offers researchers a powerful new way to explore the human proteome. This could lead to significant advancements in the understanding and treatment of cancer, cardiometabolic, and immunologic diseases.
Read also:
- Meta's AI Chatbot Boosts Content, Apple's Siri Under French Data Probe
- Europe's Energy Infrastructure Under Siege: Cyberattacks Surge 67% in 2025
- YouTube has disbursed over $100 billion to content creators on its platform since the year 2021.
- Investment of $20 million in strategy by the Aqua 1 Foundation of the UAE in Above Food
